Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 15;19(3):2267301.
doi: 10.1080/21645515.2023.2267301. Epub 2023 Oct 30.

Knowledge-map analysis of bladder cancer immunotherapy

Zongwei Lv  1 , Junhui Hou  1 , Yuan Wang  2 , Xia Wang  1 , Yibing Wang  1 , Kefeng Wang  1
Affiliations
Review

Knowledge-map analysis of bladder cancer immunotherapy

Zongwei Lv et al. Hum Vaccin Immunother. .

Abstract

This study aimed to conduct a bibliometric analysis in the field of bladder cancer (BC) immunotherapy, and explore the research trends, hotspots and frontiers from 2000 to 2022. VOSviewer software was used to analyze the collaborative relationships between authors, institutions, countries/regions, and journals through citation, co-authorship, and co-citation analysis, to identify research hotspots and frontiers in this field. Researchers based in the United States of America have published a total of 627 papers with 27,308 citations. Indeed, the USA ranked first among the top 10 most active countries and showed the most extensive collaboration with other countries. The University of Texas MD Anderson CANC CTR has published 58 articles, making it the top most institution in terms of published articles and active collaborative research. Kamat AM and Lamm DL were the most active and co-cited authors with 28 papers and 980 co-citations, respectively. Chang Yuan and Xu le were the most active collaborative authors with a total link strength of 195. The J UROLOGY was the most active and frequently co-cited journal, with 100 papers and 6,668 co-citations. Studies of BC immunotherapy can be broadly classified into three categories: "basic research", "clinical trial", and "prognosis". Our findings provide an overview of the research priorities and future directions of BC immunotherapy. Tumor microenvironment and immune checkpoint inhibitors (ICIs) of BC, as well as the combination of ICIs with other drugs, may become the main direction of future research.

Keywords: Bibliometrics; bladder cancer; diagnosis; immunotherapy; prognosis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Flow chart of the literature screening related to BC immunotherapy research.
Figure 2.
Figure 2.
Annual number of publications in BC immunotherapy from 2000 to 2022.
Figure 3.
Figure 3.
Bibliometric analysis of the co-authorship of countries/regions in the field of BC immunotherapy. (a) Network visualization map of countries/regions collaborations in the field of BC immunotherapy. (b) Overlay visualization map of countries/regions collaborations in the field of BC immunotherapy.
Figure 4.
Figure 4.
Bibliometric analysis of the co-authorship of institutions in the field of BC immunotherapy. (a) Network visualization map of collaborations among institutions in the field of BC immunotherapy. (b) Overlay visualization map of collaborations among institutions in the field of BC immunotherapy.
Figure 5.
Figure 5.
Bibliometric analysis of the co-cited authors and co-authorship of authors in the field of BC immunotherapy. (a) Density visualization map of co-cited authors in the field of BC immunotherapy. (b) Network visualization map of authors collaboration in the field of BC immunotherapy. (c) Overlay visualization map of authors collaboration in the field of BC immunotherapy.
Figure 6.
Figure 6.
Bibliometric analysis of co-cited journals in the field of BC immunotherapy. (a) Density visualization map of co-cited journals in the field of BC immunotherapy. (b) Top 10 main co-cited journals related to BC immunotherapy.
Figure 7.
Figure 7.
Density visualization map of co-cited references in the field of BC immunotherapy.
Figure 8.
Figure 8.
Bibliometric analysis of the co-occurrence of all keywords in the field of BC immunotherapy. (a) Network visualization map of high frequency keywords in the field of BC immunotherapy. (b) Overlay visualization map of high frequency keywords in the field of BC immunotherapy.
See this image and copyright information in PMC

Comment in

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A.. Cancer statistics, 2022. CA Cancer J Clin. 2022. Jan;72(1):7–12. doi:10.3322/caac.21708. - DOI - PubMed
    1. Ritch CR, Velasquez MC, Kwon D, Becerra MF, Soodana-Prakash N, Atluri VS, Almengo K, Alameddine M, Kineish O, Kava BR, et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol. 2020. Mar;203(3):505–11. doi:10.1097/JU.0000000000000593. - DOI - PubMed
    1. Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017. Mar;71(3):462–75. doi:10.1016/j.eururo.2016.06.020. - DOI - PubMed
    1. Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol. 2021 Apr 16;12:672356. doi:10.3389/fimmu.2021.672356. - DOI - PMC - PubMed
    1. Vasekar M, Degraff D, Joshi M. Immunotherapy in bladder cancer. Curr Mol Pharmacol. 2016;9(3):242–51. doi:10.2174/1874467208666150716120945. - DOI - PubMed

Publication types

Substances